cambridge.org/neu

Research Letter

Cite this article: Sher L. (2020) Dual disorders and suicide during and following the COVID-19 pandemic. *Acta Neuropsychiatrica* 1–2. doi: 10.1017/neu.2020.37

Received: 22 September 2020 Revised: 7 October 2020 Accepted: 9 October 2020

Key words:

COVID-19; suicide; dual disorders; substance use disorders

Author for correspondence:

Leo Sher, Email: Leo.Sher@mssm.edu

Dual disorders and suicide during and following the COVID-19 pandemic

Leo Sher^{1,2}

¹James J. Peters Veterans' Administration Medical Center, Bronx, NY, USA and ²Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Patients with dually diagnosed mental illness and substance use disorder are at high risk for suicidal behaviour (Abroms and Sher, 2016). For example, substance use disorders are a significant predictor of suicide attempts in patients with bipolar disorder, and the risk of suicide in patients with co-occurring bipolar and alcohol use disorder is roughly twice than that of those without alcohol use disorder (Dalton *et al.*, 2003). Patients with dual diagnosis are also more likely to have medical and neurological comorbidities, such as pain disorders and traumatic brain injuries, which further increase risk for suicidal behaviours (Abroms & Sher, 2016).

The COVID-19 pandemic may lead to relapse or exacerbation of pre-existing dual disorders and to the onset of new dual disorders. The COVID-19 crisis is associated with anxiety, fear of contagion, uncertainty, social isolation, chronic stress, economic difficulties, and other psychosocial issues which may lead to relapse or worsening of depressive, anxiety, substance use, and other psychiatric disorders in vulnerable populations, especially in individuals with dual disorders (Sher, 2020). For example, a recent study in China showed that during the COVID-19 pandemic 19% of abstinent alcohol users and 25% of abstinent smokers relapsed (Sun *et al.*, 2020). Also, 32% of regular alcohol drinkers increased alcohol consumption and 20% of regular smokers increased smoking during the pandemic. The American Medical Association Issue Brief published on 20 July 2020 stated that more than 35 U.S. States reported increases in opioid-related mortality during the COVID-19 pandemic (American Medical Association, 2020).

The COVID-19 pandemic may also lead to the onset of new dual disorders. Distressed, anxious, and depressed individuals may start using alcohol and drugs. It is important to note that substance use can lead to immune system, respiratory, and pulmonary alterations and may increase susceptibility to COVID-19.

Feelings of fear and anxiety may hold people back from seeking or continuing treatment for dual disorders. When psychiatric disorders go untreated, substance abuse typically worsens, and when someone starts using more drugs or alcohol, their psychiatric disorders worsen. The Coronavirus disease crisis may increase suicidality among patients with dual disorders during and after the pandemic. It is a perfect storm situation: the COVID-19 pandemic may increase suicide risk in persons with dual disorders who are already at elevated suicide risk.

To reduce suicides among individuals with dual disorders in the COVID-19 epoch we need to

- improve recognition of dual disorders. Unrecognised and untreated individuals with dual disorders may be at a specially high suicide risk;
- screen dual disorders patients for suicidal ideation;
- adequately treat dual disorders;
- prevent a relapse when the patient is in remission; this is especially important in the stressful COVID-19 era;
- treat comorbid medical and neurological disorders;
- provide social support; it is vital to reduce social isolation/loneliness during the COVID-19 epidemic;
- provide dual disorders patients with information about suicide prevention hotlines and other available mental health resources;
- reduce access to lethal means, if possible.

Psychiatric consequences of the COVID-19 disaster including increase in suicides are probably to be present for a lengthy time and peak later than the actual COVID-19 pandemic. Although suicide prevention is a very difficult task, clinicians are expected to make every effort to prevent suicide in their patients.

References

Abroms M and Sher L (2016) Dual disorders and suicide. *Journal of Dual Diagnosis* 12(2), 148–149. doi: 10.1080/ 15504263.2016.1172898

© Scandinavian College of Neuropsychopharmacology 2020.



- American Medical Association (2020) Issue Brief: Reports of Increases in Opioid-Related Overdose and Other Concerns During COVID Pandemic. Available at https://www.ama-assn.org/system/files/2020-07/issue-briefincreases-in-opioid-related-overdose.pdf (accessed 2 August 2020).
- Dalton EJ, Cate-Carter TD, Mundo E, Parikh SV and Kennedy JL (2003) Suicide risk in bipolar patients: the role of co-morbid substance use disorders. *Bipolar Disorders* 5(1), 58–61. doi: 10.1034/j.1399-5618.2003.00017.x
- Sher L (2020) The impact of the COVID-19 pandemic on suicide rates. QJM: An International Journal of Medicine 113(10), 707–712. doi: 10.1093/qjmed/ hcaa202
- Sun Y, Li Y, Bao Y, Meng S, Sun Y, Schumann G, Kosten T, Strang J, Lu L and Shi J (2020) Brief Report: Increased addictive Internet and substance use behavior during the COVID-19 pandemic in China. *American Journal on Addictions* 29(4), 268–270. doi: 10.1111/ajad.13066